501 related articles for article (PubMed ID: 16556174)
1. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
3. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
4. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
5. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
6. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680
[TBL] [Abstract][Full Text] [Related]
7. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
8. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2007 May; 39(5):415-21. PubMed ID: 17379591
[TBL] [Abstract][Full Text] [Related]
9. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; MartÃnez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
10. The effect of photodynamic therapy (PDT) on oesophageal motility and acid clearance in patients with Barrett's oesophagus.
Globe J; Smythe A; Kelty CJ; Reed MW; Brown NJ; Ackroyd R
J Photochem Photobiol B; 2006 Oct; 85(1):17-22. PubMed ID: 16723253
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
12. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study.
Martinek J; Benes M; Brandtl P; Hucl T; Vasicek M; Voska L; Lanska V; Nosek V; Spicak J
Endoscopy; 2008 Sep; 40(9):711-6. PubMed ID: 18698534
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
Gurski RR; Peters JH; Hagen JA; DeMeester SR; Bremner CG; Chandrasoma PT; DeMeester TR
J Am Coll Surg; 2003 May; 196(5):706-12; discussion 712-3. PubMed ID: 12742201
[TBL] [Abstract][Full Text] [Related]
16. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
17. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
19. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.
El-Serag HB; Aguirre TV; Davis S; Kuebeler M; Bhattacharyya A; Sampliner RE
Am J Gastroenterol; 2004 Oct; 99(10):1877-83. PubMed ID: 15447744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
